|
Molecular Insight Pharmaceuticals currently has three oncology clinical trials underway:
Phase I/II Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed or Refractory High-Risk Neuroblastoma
Phase I study Evaluating the Safety, Pharmacokinetics, Tissue Distribution, Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen: Determination of I-123 Radiation Dosimetry for 123-I-MIP-1072 and 123-I-MIP-1095
|